Insmed (NASDAQ:INSM) Announces Quarterly Earnings Results

Insmed (NASDAQ:INSM) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $499.06 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. During the same quarter last year, the business earned ($1.75) earnings per share. The company’s revenue was up 268.4% on a year-over-year basis.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI’s launch continues to materially outperform expectations: Third-quarter revenue reached $400.1 million, up 29% sequentially, and the product surpassed $1 billion in its first four full quarters. Insmed raised 2026 BRINSUPRI guidance to $1.35 billion-$1.4 billion.
• ARIKAYCE also delivered steady growth and faces a major potential market expansion. Third-quarter revenue rose 9% year over year to $124.4 million, prompting higher 2026 guidance of $460 million-$470 million; FDA priority review for a broader MAC lung disease label has a January 28, 2027 action date.
• Insmed expects to reach cash-flow positivity in 2027. The company ended the quarter with approximately $1.1 billion in cash, while management said BRINSUPRI’s growth should improve operating leverage even as investments continue across the pipeline.
• The long-term pipeline remains a significant growth driver, led by TPIP. TPIP’s four Phase 3 studies are advancing, with the PH-ILD trial more than 35% enrolled and ahead of schedule; management estimates more than $6 billion in peak sales potential, although approvals and clinical outcomes remain uncertain.
• Insmed is pursuing a large but still unquantified expansion of BRINSUPRI’s opportunity in COPD and asthma patients with undiagnosed comorbid bronchiectasis. AI diagnostic tools, imaging studies, physician education and other initiatives are underway, with initial findings expected around mid-2027; management characterized the opportunity as substantial but acknowledged that adoption will take time.

Insmed Price Performance

INSM stock traded up $14.61 during mid-day trading on Thursday, hitting $111.59. 11,208,179 shares of the stock were exchanged, compared to its average volume of 2,982,364. The business has a fifty day moving average price of $113.29 and a 200 day moving average price of $126.28. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The stock has a market capitalization of $24.37 billion, a price-to-earnings ratio of -27.15 and a beta of 0.83.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on INSM shares. Wolfe Research downgraded Insmed from an “outperform” rating to a “peer perform” rating in a research report on Monday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Thursday, October 15th. Bank of America restated a “buy” rating and set a $207.00 target price on shares of Insmed in a research report on Monday, October 12th. JPMorgan Chase & Co. lowered their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, August 10th. Finally, Roth Capital reissued a “buy” rating and set a $198.00 target price (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $197.26.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Brennan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raised outlook and strong BRINSUPRI growth: Insmed increased its 2026 revenue guidance for BRINSUPRI to $1.35 billion-$1.40 billion and for ARIKAYCE to $460 million-$470 million. BRINSUPRI generated $400.1 million in third-quarter revenue, up 29% from the second quarter. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Revenue exceeded expectations: Total third-quarter revenue reached $524.4 million, up 268.4% year over year and above the roughly $499.1 million analyst consensus. ARIKAYCE revenue rose 9% year over year to $124.4 million. Insmed Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Loss narrowed substantially: Insmed reported a third-quarter loss of $0.46 per share, compared with a $1.75 loss in the year-earlier period. The company also launched BRINSUPRI tablets in Japan, adding a potential international growth opportunity. Insmed Raises FY26 Revenue Outlook for BRINSUPRI and ARIKAYCE
• Neutral Sentiment: Unusually high call-option activity: Traders purchased 7,706 call options, 121% above average volume. This indicates increased bullish speculation, but options activity alone does not establish a fundamental change in valuation.
• Negative Sentiment: Quarterly EPS missed estimates: The $0.46 per-share loss was wider than the consensus estimate of a $0.39 loss, creating a counterpoint to the revenue and guidance strength. Insmed Quarterly Earnings Report
• Negative Sentiment: Analyst price-target reduction: Raymond James lowered its Insmed price target from $187 to $173, signaling more cautious valuation expectations. Raymond James Cuts Target for Insmed Stock

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.